Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease
Cerebrospinal fluid (CSF) concentrations of total Tau and Tau phosphorylated at threonine (position 181 [pTau181]) were studied with ELISA in a group of carefully selected patients with a neurochemically supported diagnosis of Alzheimer’s disease (AD, n=9; age range, 51–89 yr) and in a group of sex- and age-matched nondemented controls (n=9; age range, 52–81 yr). The concentration of both biomarkers is increased significantly in the AD group (total Tau, p<0.0008; pTau181, p<0.008). A significant correlation between CSF concentrations of both biomarkers is observed (R=0.897; p<0.001). Neither total Tau nor pTau181 correlates with age or degree of memory impairment, and only a tendency is observed between the concentrations of total Tau and Aβ42 in the CSF. Our results further confirm a possible role of pTau181 as a diagnostic tool in AD. The current literature regarding the physiological and pathological role of phosphorylated Tau proteins is reviewed, as well as the role of these proteins as promising biomarkers in the diagnosis of neurodegenerative disorders.
Index EntriesAlzheimer’s dementia cerebrospinal fluid Tau neurofibrillary tangles
Unable to display preview. Download preview PDF.
- Consensus Report (1998) Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer’s Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol. Aging 19, 109–116.CrossRefGoogle Scholar
- Drewes G., Trinczek B., Illenberger S., Biernat J., Schmitt-Ulms G., Meyer H. E., et al. (1995) Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J. Biol. Chem. 270, 7679–7688.PubMedCrossRefGoogle Scholar
- Lewczuk P., Esselmann H., Meyer M., Wollscheid V., Neumann M., Otto M., et al. (2003) The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid (CSF) in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun. Mass Spectrom. 17, 129–196.CrossRefGoogle Scholar
- McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–944.PubMedGoogle Scholar
- Riemenschneider M., Schmolke M., Lautenschlager N., Guder W. G., Vanderstichele H., Vanmechelen E., and Kurz A. (2000) Cerebrospinal beta-amyloid (1–42) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284, 85–88.PubMedCrossRefGoogle Scholar
- Rosner H., Rebhan M., Vacun G., and Vanmechelen E. (1995) Developmental expression of tau proteins in the chicken and rat brain: rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms. Int. J. Dev. Neurosci. 13, 607–617.PubMedCrossRefGoogle Scholar
- Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjogren M., et al. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49–52.PubMedCrossRefGoogle Scholar
- Vanmechelen E., Van Kerschaver E., Blennow K., De Deyn P. P., Gartner F. H., Parnetti L., et al. (2001b) CSF-Phospho-tau (181P) as a promising marker for discriminating Alzheimer’s disease from dementia with Lewy bodies, in Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics, Iqbal, K., Sisodia, S. S., and Winblad, B., eds., John Wiley and Sons Ltd., Chichester, UK, pp. 285–291.Google Scholar
- Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., et al. (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated A beta peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481–496.PubMedCrossRefGoogle Scholar